Compare · BCDA vs RVMD
BCDA vs RVMD
Side-by-side comparison of BioCardia Inc. (BCDA) and Revolution Medicines Inc. (RVMD): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BCDA and RVMD operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- RVMD is the larger of the two at $40.57B, about 2855.2x BCDA ($14.2M).
- Over the past year, BCDA is down 36.6% and RVMD is up 229.0% - RVMD leads by 265.6 points.
- RVMD has been more active in the news (12 items in the past 4 weeks vs 9 for BCDA).
- RVMD has more recent analyst coverage (25 ratings vs 1 for BCDA).
- Company
- BioCardia Inc.
- Revolution Medicines Inc.
- Price
- $0.92-1.18%
- $178.07-5.91%
- Market cap
- $14.2M
- $40.57B
- 1M return
- -17.86%
- -9.54%
- 1Y return
- -36.55%
- +229.03%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2020
- News (4w)
- 9
- 12
- Recent ratings
- 1
- 25
BioCardia Inc.
BioCardia, Inc., a clinical-stage regenerative medicine company, develops therapeutics for cardiovascular diseases. Its lead therapeutic candidate is the CardiAMP Cell Therapy System for the treatment of heart failure and chronic myocardial ischemia; and ALLOGENEIC cell therapy for cardiac and pulmonary disease. The company is also developing ALLOGENEIC Cell Therapy System, an investigational culture expanded bone marrow derived mesenchymal cell therapy, which is in Phase I/II trial for the treatment of ischemic systolic heart failure. In addition, it offers the Helix biotherapeutic delivery system, a percutaneous catheter delivery system for cardiovascular regenerative medicine; and Morph deflectable guides and sheaths. The company is based in San Carlos, California.
Revolution Medicines Inc.
Revolution Medicines, Inc., a clinical-stage precision oncology company, focuses on developing therapies to inhibit frontier targets in RAS-addicted cancers. The company is developing RMC-4630, an inhibitor of SHP2, which is in Phase 1/2 clinical trial for the treatment of solid tumors, such as gynecologic and colorectal cancer tumors. It also develops RMC-5845, a selective inhibitor of SOS1, a protein that converts RAS (OFF) to RAS (ON) in cells; and RMC-5552, a hyperactivated selective inhibitor of mTORC1 signaling in tumors. In addition, the company is developing RMC-6291, a mutant-selective inhibitor of KRASG12C(ON) and NRASG12C(ON); and RMC-6236, a RAS-selective inhibitor of multiple RAS(ON) variants. Further, it develops RAS(ON) Inhibitors targeting KRASG13C(ON) and KRASG12D(ON). Revolution Medicines, Inc. has a collaboration agreement with Sanofi for the research and development of SHP2 inhibitors, including RMC-4630. The company was incorporated in 2014 and is headquartered in Redwood City, California.
Latest BCDA
- SEC Form 8-K filed by BioCardia Inc.
- BioCardia Presents CardiAMP HF II Trial Design at Heart Failure Society of America Annual Scientific Meeting
- BioCardia Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- BioCardia Files Revised De Novo Pre-Submission for FDA Approval of Helix™ Catheter
- President and CEO Altman Peter bought $1,030 worth of shares (1,000 units at $1.03), increasing direct ownership by 0.26% to 384,885 units (SEC Form 4)
- President and CEO Altman Peter bought $1,995 worth of shares (1,900 units at $1.05), increasing direct ownership by 0.50% to 383,885 units (SEC Form 4)
- BioCardia Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- BioCardia Confirms Timing and Provides Update on FDA Helix Pre-Submission and PMDA CardiAMP HF Shonin Submission
- BioCardia Inc. filed SEC Form 8-K: Other Events
- BioCardia Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
Latest RVMD
- William Blair initiated coverage on Revolution Medicines
- Revolution Medicines’ RASONQUE(™) (daraxonrasib) Receives Positive CHMP Opinion Recommending Marketing Authorization in European Union for Metastatic Pancreatic Cancer
- Cancer Drug Spending Is Headed Past $400 Billion as Colorectal and Pancreatic Cancers Move Up the Research Agenda
- SEC Form 8-K filed by Revolution Medicines Inc.
- Revolution Medicines Begins Treating Patients in Phase 3 RASolute 309 Trial Evaluating RASONQUE™ (daraxonrasib) Plus Zoldonrasib as First-Line Treatment for Metastatic RAS G12D Pancreatic Cancer
- Chief Development Officer Sandler Alan B. exercised 6,000 shares at a strike of $58.84 and sold $1,275,294 worth of shares (6,309 units at $202.14) as part of a pre-agreed trading plan, decreasing direct ownership by 0.58% to 52,559 units (SEC Form 4)
- SVP & General Counsel Cislini Jeff sold $158,600 worth of shares (765 units at $207.32) as part of a pre-agreed trading plan, decreasing direct ownership by 1% to 51,776 units (SEC Form 4)
- Officer Mancini Anthony sold $743,285 worth of shares (3,708 units at $200.45) as part of a pre-agreed trading plan and exercised 3,121 shares at a strike of $33.62, decreasing direct ownership by 1% to 39,765 units (SEC Form 4)
- KRAS Inhibitor Market Projected to Reach $7.8 Billion by 2034
- Director Anderson Elizabeth M exercised 5,070 shares at a strike of $1.12 and sold $1,958,016 worth of shares (10,143 units at $193.04) as part of a pre-agreed trading plan, decreasing direct ownership by 54% to 4,333 units (SEC Form 4)